A Service For Professionals Tuesday, August 22, 2017
Contact (202) 540-8337

Pharmaceutical Industry Today

A Service For Professionals Tuesday, August 22, 2017 11449 Sources 399,640,931 Articles 3,328,029 Readers
Contact (202) 540-8337

Hemispherx Biopharma to Host Conference Call to Discuss Second Quarter Financial Results on Tuesday, August 15, 2017

Financials for Second Quarter Ended June 30, 2017 will be released on August 14, 2017

PHILADELPHIA, Aug. 11, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announced today that it anticipates filing its 2017 second quarter financial results for quarter ended June 30 on Monday, August 14, 2017.  Hemispherx will host a conference call at 1:00 p.m. Eastern Daylight Time (EDT) on Tuesday, August 15, 2017 to provide a general business update. Hemispherx will respond to various stockholder questions submitted prior to the call. 

An audio replay of the conference call will be available on the Company’s website approximately one hour following the conclusion of the call.

Conference Call Information

Date:  Tuesday, August 15, 2017
Time:  1:00 PM EDT
Dial-in numbers:  800-346-7359 (domestic)
  973-528-0008 (international)
Conference number:  27781
Questions: ir@hemispherx.net by 5:00 PM EDT on Monday, August 14, 2017
Audio Replay: http://ir.hemispherx.net/Events_Presentations

About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx’s flagship products include Alferon N Injection® and the experimental therapeutic rintatolimod (tradenames Ampligen® or Rintamod®). Rintatolimod is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Hemispherx’s platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Because rintatolimod is experimental in nature, it is not designated safe and effective by the FDA for general use and is legally available only through clinical trials.

Cautionary Statement
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties.  For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.  Any forward-looking statements set forth in this press release speak only as of the date of this press release.  We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.hemispherx.net. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

/EIN News/ --

Company/Investor Contact 
                    Charles Jones 
                    CJones & Associates Public Relations 
                    Office: 888-557-6480
                    Cell: 305-987-7418
                    Email: cjones@cjonespr.com

Primary Logo

Powered by EIN News